1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma
P.A. Ascierto, Stephan Grabbe, Michele Guida, Fabrizio Carnevale Schianca, P. Rutkowski, A.M. Arance Fernandez, Janet L. Markman, V. Chen, Hushan Yang, Katarina Ćuk, M.A. Kaczorowska, Isabel Büttel, S. Liebscher, Michael J. Wenger, I. Lowy, Frank Seebach, P. Brück, Ö. Türeci, Uğur Şahin, G.V. Long
Topics & Concepts
MedicineMelanomaOncologyNuclear medicineInternal medicineRadiologyRandomized controlled trialPhases of clinical researchPhase (matter)Clinical trialMelanoma and MAPK PathwaysCancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management